Ankasa Regenerative Therapeutics, Inc.
Recombinant human Wnt proteins for therapeutic use
Follows are private to you and power your alerts
Updated · ankasaregenerativetherapeutics.com
- Sector
- Biotech
- Headquarters
- LA JOLLA, CA
- Founded
- 2014
- Latest Form D
- $6M, Oct 2020
- Total capital
- $15.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $15.5M
- 2 Form D · last Oct 2020
- 72 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$6M
- Private capital raisedForm D · SEC · 1st filing$9.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Andre J. Kobelt, Ph.D.DirectorNamed in SEC Form D filings
- Douglas J. DownsExecutive Officer, DirectorNamed in SEC Form D filings
- Kevin J. KinsellaDirectorNamed in SEC Form D filings
- Sanford J. MadiganExecutive Officer, DirectorNamed in SEC Form D filings
- Tighe J. ReardonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 4- PendingWnt Compositions And Methods Of Process From Serum-free Culturing ConditionsUSPTOApplication 16996676
- PendingWnt Compositions And Methods Of Process From Serum-free Culturing ConditionsUSPTOApplication PCTUS2018044886
- PendingWnt Compositions And Methods Of Process From Serum-free Culturing ConditionsUSPTOApplication 62630448
Show all 4 patent records
- Wnt Compositions And Methods Of Process From Serum-free Culturing ConditionsDec 24, 2020 · Application 16996676Pending
- Wnt Compositions And Methods Of Process From Serum-free Culturing ConditionsApplication PCTUS2018044886Pending
- Wnt Compositions And Methods Of Process From Serum-free Culturing ConditionsApplication 62630448Pending
- Wnt Compositions And Methods Of Process From Serum-free Culturing ConditionsApplication 62539960Pending
Related companies, and why
- Reunion NeuroscienceSimilar federal contract value in Biotech · null in contracts
- Clene Inc.Similar federal contract value in Biotech · null in contracts
- Icagen-T, Inc.Similar federal contract value in Biotech · null in contracts
- Endogena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SystImmune, Inc.Similar federal contract value in Biotech · null in contracts
- Paragon Biosciences Qlarity Capital, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .